DHGR (Devonian Health Group) Debt-to-EBITDA : (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHGR Devonian Health Group Inc DHGR
59 GF Score
Price $5.88
GF Value $2.06
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Devonian Health Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Devonian Health Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.06 Mil. Devonian Health Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.04 Mil. Devonian Health Group's annualized EBITDA for the quarter that ended in Apr. 2026 was $-5.50 Mil. Devonian Health Group's annualized Debt-to-EBITDA for the quarter that ended in Apr. 2026 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Devonian Health Group's Debt-to-EBITDA or its related term are showing as below:

DHGR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.07   Med: -1.82   Max: 35.65
Current: -0.02

During the past 10 years, the highest Debt-to-EBITDA Ratio of Devonian Health Group was 35.65. The lowest was -4.07. And the median was -1.82.

DHGR's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs DHGR: -0.02

Devonian Health Group  (AMEX:DHGR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Devonian Health Group Debt-to-EBITDA Related Terms

Devonian Health Group Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Devonian Health Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devonian Health Group Debt-to-EBITDA Chart

Devonian Health Group Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Devonian Health Group Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

DHGR vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Devonian Health Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Devonian Health Group Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Devonian Health Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Devonian Health Group's Debt-to-EBITDA falls into.


DHGR
59GF Score
Devonian Health Group Inc DHGR
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Devonian Health Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Devonian Health Group's Debt-to-EBITDA for the fiscal year that ended in Jul. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.034463853025207 + 0.056530324400564) / -3.5750748987461
=-0.03

Devonian Health Group's annualized Debt-to-EBITDA for the quarter that ended in Apr. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.059235912129895 + 0.044021012416428) / -5.4975730462344
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.

Is Devonian Health Group (DHGR) Overvalued in 2026?

Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued. The current stock price of $5.88 is trading 185.2% above its estimated GF Value™ of $2.06. GuruFocus considers Devonian Health Group to be Significantly Overvalued.

Key valuation signals for DHGR:

  • Debt-to-EBITDA:
  • GF Value™: $2.06 vs. price of $5.88 (185.2% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the DHGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Devonian Health Group Business Description

Other Exchanges GSD:Canada
Address 360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
59GF Score

Get the complete analysis for DHGR

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.88
Price
$2.06
GF Value